Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Hindi Outcomes from efforts at advancing capacity for manufacturing quality medicines in sub-Saharan Africa - the BIRS program
*Corresponding Author:
Copyright: © 2020 . This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Abstract
Some low-income economies, within sub-Saharan Africa employ anti-counterfeiting devices to determine prevalence of spurious and falsified medicinal products. This is considered a lagging, reactive measure to access quality of health commodities. A more pro-active measure, which trains professionals that are relevant in the healthcare sector, was introduced within the sub region. The Purdue Biotechnology Innovation and Regulatory Science (BIRS) Master’s program provides advanced pharmaceutical education which aims to reduce the prevalence of spurious medicines by building human capacity to initiate and sustain manufacturing quality medicines within African sub-region. Participants are drawn from national regulatory bodies, pharmaceutical industries and academia. The BIRS training equips them in Pharmaceutical Good Manufacturing Practices (GMP) as well as other quality assurance principles to enable the sub-region attain international standards. In this mixed method research, we used qualitative case studies to access the impact of BIRS training with a purposeful convenient sampling of alumni students in the areas of pharmaceutical
manufacturing and quality control. Parametric quantitative method was also used to test our hypothesis that the program participants will significantly increase over years if it was meeting set objectives within sub-Saharan Africa. The results indicated that the alumni from ten countries have implemented and sustained remarkable projects in the area of Pharmaceutical GMP and laboratory quality controls. Furthermore, participants from 2016 (Males = 17, Females = 8), to 2018 (14, 8), increased in year 2020 (31, 22), p-values (less than 0.1, α = 0.1). We concluded the program is impacting sustainable medicines initiative in sub-Saharan Africa.
